BioPharma Dive ١٤ يناير ٢٠٢٦ Caldera starts up with $112.5M and a dual-targeting immune drug from China
BioPharma Dive ١٢ يناير ٢٠٢٦ JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year
BioPharma Dive ١٢ يناير ٢٠٢٦ AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
BioPharma Dive ١٢ يناير ٢٠٢٦ Best practices for COA selection: Building a stronger foundation for clinical trials
BioPharma Dive ٩ يناير ٢٠٢٦ Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies
BioPharma Dive ٨ يناير ٢٠٢٦ Parabilis, chasing ‘undruggable’ targets, nabs $305M amid VC funding blitz